TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states... Show more
a developer of a proprietary system for preserving human organs for transplant
Industry MedicalNursingServices
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AVXC | 84.01 | 1.20 | +1.45% |
| Avantis Emerging Markets Ex-Chn Eq ETF | |||
| EQRR | 86.87 | 0.95 | +1.11% |
| ProShares Equities for Rising Rates ETF | |||
| JMEE | 75.60 | 0.57 | +0.76% |
| JPMorgan Small & Mid Cap Enh Eq ETF | |||
| GOEX | 90.42 | 0.28 | +0.31% |
| Global X Gold Explorers ETF | |||
| UECG | 3.49 | -0.42 | -10.79% |
| Leverage Shares 2X Long UEC Daily ETF | |||
A.I.dvisor indicates that over the last year, TMDX has been loosely correlated with ATEC. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if TMDX jumps, then ATEC could also see price increases.
| Ticker / NAME | Correlation To TMDX | 1D Price Change % | ||
|---|---|---|---|---|
| TMDX | 100% | -3.36% | ||
| ATEC - TMDX | 44% Loosely correlated | +19.68% | ||
| PODD - TMDX | 36% Loosely correlated | -2.02% | ||
| RDNT - TMDX | 35% Loosely correlated | +1.63% | ||
| SMTI - TMDX | 34% Loosely correlated | -0.31% | ||
| ALGN - TMDX | 33% Loosely correlated | +0.07% | ||
More | ||||
| Ticker / NAME | Correlation To TMDX | 1D Price Change % |
|---|---|---|
| TMDX | 100% | -3.36% |
| Medical/Nursing Services industry (141 stocks) | 8% Poorly correlated | +0.38% |
| Health Services industry (242 stocks) | 8% Poorly correlated | +0.38% |
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where TMDX declined for three days, in 276 of 345 cases, the price declined further within the following month. The odds of a continued downward trend are 80%.
The 10-day RSI Indicator for TMDX moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 32 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Momentum Indicator moved below the 0 level on August 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TMDX as a result. In 71 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for TMDX turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 40 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +6.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMDX advanced for three days, in 259 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
TMDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 242 of 278 cases where TMDX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
The Tickeron SMR rating for this company is 28 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. TMDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.501) is normal, around the industry mean (10.685). P/E Ratio (21.290) is within average values for comparable stocks, (67.907). Projected Growth (PEG Ratio) (0.704) is also within normal values, averaging (3.653). TMDX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (4.724) is also within normal values, averaging (35.925).
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.